Zhou, Huixing
Wang, Yafei
Chen, Jiao
He, Aili
Jin, Jie
Lu, Quanyi
Zhao, Ying
Li, Junjun
Hou, Ming
Su, Liping
Lai, Xun
Wang, Wei
Liu, Lihong
Ma, Yanping
Gao, Da
Lai, Wenhong
Zhou, Xin
Jing, Hongmei
Zhang, Jinqiao
Yang, Wei
Ran, Xuehong
Lin, Congmeng
Hao, Jianping
Xiao, Taiwu
Huang, Zhenqian
Zhu, Zhigang
Wang, Qing
Fang, Baijun
Wang, Binghua
Song, Yanping
Cai, Zhen
Liu, Bo
Zhu, Yanan
Yang, Xinai
Kang, Xiaoyan
Li, Juan
Chen, Wenming http://orcid.org/0000-0001-6298-8489
Funding for this research was provided by:
Qilu Pharmaceutical Co. Ltd
Article History
Received: 10 August 2023
Accepted: 18 November 2023
First Online: 19 December 2023
Declarations
:
: All authors have read the manuscript and made the decision to submit it for publication. The corresponding author had final responsibility for the decision to submit for publication.
: This trial was designed through collaboration between the investigators and Qilu Pharmaceutical Co., Ltd., the manufacturer of generic pomalidomide in Jinan, China. The study's design was a joint effort between the sponsor and the study committee. Wenming Chen, Juan Li, Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, and Zhen Cai received research funding from Qilu Pharmaceutical Co. Ltd. Moreover, Bo Liu, Yanan Zhu, Xinai Yang, and Xiaoyan Kang were employees of Qilu Pharmaceutical Co. Ltd. All authors declare that they have no other competing interests.